Revenue and Growth Achievements
Viatris reported a full-year revenue growth of 2% on a divestiture adjusted operational basis, achieving total revenues of approximately $14.7 billion with an adjusted EBIT of approximately $4.7 billion and adjusted EPS of $2.65 per share. New product revenues reached $582 million.
Debt Reduction and Capital Return
The company retired approximately $3.7 billion of debt and returned approximately $825 million in capital to shareholders through dividends and share repurchases.
Pipeline and R&D Progress
Viatris expanded its innovative portfolio with three new products and has 10 unique molecules in Phase 3 clinical development. They expect several Phase 3 readouts in 2025.
Anticipated Share Repurchases
The company plans to return $1 billion to $1.2 billion to shareholders through dividends and share buybacks in 2025, with a targeted $500 million to $650 million in share repurchases.
Strong Free Cash Flow and Leverage Management
Viatris generated free cash flow of approximately $2.6 billion and achieved a gross leverage target, with a year-end leverage ratio of approximately 2.9 times.